Nuclear receptor ligands in therapy of cholestatic liver disease

Frontiers in Bioscience

Volumn 14, Issue 11, 2009, Pages 4299-4325

  Sturm, Ekkehard ^a   Wagner, Martin ^b   Trauner, Michael ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cholestasis; Constitutive androstane receptor; Farnesoid X activated receptor; Nuclear receptors; Pregnane X receptor; Review

Indexed keywords

CELL RECEPTOR; LIGAND;

ANIMAL; CHOLESTASIS; DISEASE MODEL; HUMAN; LIVER DISEASE; METABOLISM; REVIEW;

ANIMALS; CHOLESTASIS; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; LIVER DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 63849111791     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3529     Document Type: Article

References (292)

1. Karpen S J: Nuclear receptor regulation of hepatic function. J. Hepatol. 36, 832-850(2002) (Pubitemid 35177416)
2. Boyer J L: New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46, 365-371(2007) (Pubitemid 46201718)
3. Goodwin B & J. T. Moore: CAR: detailing new models. Trends Pharmacol. Sci. 25, 437-441(2004) (Pubitemid 38981560)
4. Boyer J L: Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129, 735-740(2005) (Pubitemid 41102188)
5. Zollner G, H. U. Marschall, M. Wagner, M. Trauner: Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231-251(2006) (Pubitemid 44021431)
6. Hofmann A F: Biliary secretion and excretion in health and disease: current concepts. Ann. Hepatol. 6, 15-27(2007) (Pubitemid 46407485)
7. Geier A, M. Wagner, C. G. Dietrich, M. Trauner: Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 1773, 283-308(2007) (Pubitemid 46275063)
8. Zollner G & M. Trauner: Molecular mechanisms of cholestasis. Wien. Med. Wochenschr. 156, 380-385(2006) (Pubitemid 44182023)
9. McCarthy T C, X. Li, C. J. Sinal: Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J. Biol. Chem. 280, 23232-23242(2005) (Pubitemid 40853235)
10. Wagner M, P. Fickert, G. Zollner, A. Fuchsbichler, D. Silbert, O. Tsybrovskyy, K. Zatloukal, G. L. Guo, J. D. Schuetz, F. J. Gonzalez, H. U. Marschall, H. Denk, M. Trauner: Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile ductligated mice. Gastroenterology 125, 825-838(2003) (Pubitemid 37070700)
11. Trauner M, M. Wagner, P. Fickert, G. Zollner: Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 39, S111-S124 (2005) (Pubitemid 40397024)
12. Barbier O, L. Villeneuve, V. Bocher, C. Fontaine, I. P. Torra, C. Duhem, V. Kosykh, J. C. Fruchart, C. Guillemette, B. Staels: The UDP- glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem. 278, 13975-13983(2003) (Pubitemid 36799940)
13. Barbier O, I. P. Torra, A. Sirvent, T. Claudel, C. Blanquart, D. Duran-Sandoval, F. Kuipers, V. Kosykh, J. C. Fruchart, B. Staels: FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124, 1926-1940(2003) (Pubitemid 36666787)
14. Song C S, I. Echchgadda, B. S. Baek, S. C. Ahn, T. Oh, A. K. Roy, B. Chatterjee: Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 276, 42549-42556(2001)
15. Runge-Morris M & T. A. Kocarek: Regulation of sulfotransferases by xenobiotic receptors. Curr. Drug Metab 6, 299-307(2005) (Pubitemid 41086764)
16. Runge-Morris M, W. Wu, T. A. Kocarek: Regulation of rat hepatic hydroxysteroid sulfotransferase (SULT2-40/41) gene expression by glucocorticoids: evidence for a dual mechanism of transcriptional control. Mol. Pharmacol. 56, 1198-1206(1999)
17. Saini S P, J. Sonoda, L. Xu, D. Toma, H. Uppal, Y. Mu, S. Ren, D. D. Moore, R. M. Evans, W. Xie: A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 65, 292-300(2004) (Pubitemid 38134256)
18. Assem M, E. G. Schuetz, M. Leggas, D. Sun, K. Yasuda, G. Reid, N. Zelcer, M. Adachi, S. Strom, R. M. Evans, D. D. Moore, P. Borst, J. D. Schuetz: Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 279, 22250-22257(2004) (Pubitemid 38679421)
19. Chatterjee B, I. Echchgadda, C. S. Song: Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400, 165-191(2005) (Pubitemid 43052421)
20. Echchgadda I, C. S. Song, A. K. Roy, B. Chatterjee: Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol. Pharmacol. 65, 720-729(2004) (Pubitemid 38264040)
21. Inagaki T, M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. Jones, B. Goodwin, J. A. Richardson, R. D. Gerard, J. J. Repa, D. J. Mangelsdorf, S. A. Kliewer: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2, 217-225(2005)
22. Holt J A, G. Luo, A. N. Billin, J. Bisi, Y. Y. McNeill, K. F. Kozarsky, M. Donahee, D. Y. Wang, T. A. Mansfield, S. A. Kliewer, B. Goodwin, S. A. Jones: Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581-1591(2003) (Pubitemid 36828786)
23. Lee J, F. Azzaroli, L. Wang, C. J. Soroka, A. Gigliozzi, K. D. Setchell, W. Kramer, J. L. Boyer: Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology 121, 1473-1484(2001) (Pubitemid 33140464)
24. van Aubel R A, P. H. Smeets, J. G. Peters, R. J. Bindels, F. G. Russel: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13, 595-603(2002) (Pubitemid 34183923)
25. Denk G U, C. J. Soroka, Y. Takeyama, W. S. Chen, J. D. Schuetz, J. L. Boyer: Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J. Hepatol. 40, 585-591(2004) (Pubitemid 38367779)
26. Chen F, L. Ma, P. A. Dawson, C. J. Sinal, E. Sehayek, F. J. Gonzalez, J. Breslow, M. Ananthanarayanan, B. L. Shneider: Liver receptor homologue-1 mediates species-and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278, 19909-19916(2003) (Pubitemid 36799181)
27. Neimark E, F. Chen, X. Li, B. L. Shneider: Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40, 149-156(2004) (Pubitemid 38877576)
28. Jung D, M. Fried, G. A. Kullak-Ublick: Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277, 30559-30566(2002) (Pubitemid 34970749)
29. Jung D, A. C. Fantin, U. Scheurer, M. Fried, G. A. Kullak-Ublick: Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 53, 78-84(2004) (Pubitemid 38083014)
30. Soroka C J, J. M. Lee, F. Azzaroli, J. L. Boyer: Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33, 783-791(2001) (Pubitemid 32246625)
31. Boyer J L, M. Trauner, A. Mennone, C. J. Soroka, S. Y. Cai, T. Moustafa, G. Zollner, J. Y. Lee, N. Ballatori: Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am. J. Physiol Gastrointest. Liver Physiol 290, G1124-G1130 (2006) (Pubitemid 43788293)
32. Marschall H U, M. Wagner, K. Bodin, G. Zollner, P. Fickert, J. Gumhold, D. Silbert, A. Fuchsbichler, J. Sjovall, M. Trauner: Fxr (-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J. Lipid Res. 47, 582-592(2006) (Pubitemid 43345599)
33. Stedman C, C. Liddle, S. Coulter, J. Sonoda, J. G. Alvarez, R. M. Evans, M. Downes: Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U. S. A 103, 11323-11328(2006) (Pubitemid 44156516)
34. Zollner G, M. Wagner, P. Fickert, A. Geier, A. Fuchsbichler, D. Silbert, J. Gumhold, K. Zatloukal, A. Kaser, H. Tilg, H. Denk, M. Trauner: Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am. J. Physiol Gastrointest. Liver Physiol 289, G798-G805 (2005) (Pubitemid 41532572)
35. Sonoda J, W. Xie, J. M. Rosenfeld, J. L. Barwick, P. S. Guzelian, R. M. Evans: Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR) Proc. Natl. Acad. Sci. U. S. A 99, 13801-13806(2002) (Pubitemid 35215461)
36. Stedman C A, C. Liddle, S. A. Coulter, J. Sonoda, J. G. Alvarez, D. D. Moore, R. M. Evans, M. Downes: Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. U. S. A 102, 2063-2068(2005) (Pubitemid 40262012)
37. Zhou C, M. M. Tabb, E. L. Nelson, F. Grun, S. Verma, A. Sadatrafiei, M. Lin, S. Mallick, B. M. Forman, K. E. Thummel, B. Blumberg: Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest 116, 2280-2289(2006) (Pubitemid 44162338)
38. Uppal H, S. P. Saini, A. Moschetta, Y. Mu, J. Zhou, H. Gong, Y. Zhai, S. Ren, G. K. Michalopoulos, D. J. Mangelsdorf, W. Xie: Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45, 422-432(2007) (Pubitemid 46374599)
39. Park Y J, M. Qatanani, S. S. Chua, J. L. Larey, S. A. Johnson, M. Watanabe, D. D. Moore, Y. K. Lee: Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis. Hepatology (2008)
40. Inagaki T, A. Moschetta, Y. K. Lee, L. Peng, G. Zhao, M. Downes, R. T. Yu, J. M. Shelton, J. A. Richardson, J. J. Repa, D. J. Mangelsdorf, S. A. Kliewer: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A 103, 3920-3925(2006) (Pubitemid 43376656)
41. Kim I, S. H. Ahn, T. Inagaki, M. Choi, S. Ito, G. L. Guo, S. A. Kliewer, F. J. Gonzalez: Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664-2672(2007) (Pubitemid 350272851)
42. Kim M S, J. Shigenaga, A. Moser, K. Feingold, C. Grunfeld: Repression of farnesoid X receptor during the acute phase response. J. Biol. Chem. 278, 8988-8995(2003) (Pubitemid 36800376)
43. Beigneux A P, A. H. Moser, J. K. Shigenaga, C. Grunfeld, K. R. Feingold: Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. 293, 145-149(2002) (Pubitemid 34694183)
44. Beigneux A P, A. H. Moser, J. K. Shigenaga, C. Grunfeld, K. R. Feingold: The acute phase response is associated with retinoid X receptor repression in rodent liver. J. Biol. Chem. 275, 16390-16399(2000) (Pubitemid 30366957)
45. Zhou M, R. Wu, W. Dong, A. Jacob, P. Wang: Endotoxin downregulates peroxisome proliferator-activated receptor-gamma via the increase in TNF-alpha release. Am. J. Physiol Regul. Integr. Comp Physiol 294, R84-R92 (2008)
46. Gupta S, R. T. Stravitz, P. Dent, P. B. Hylemon: Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun. N-terminal kinase pathway. J. Biol. Chem. 276, 15816-15822(2001)
47. Ghose R, T. L. Zimmerman, S. Thevananther, S. J. Karpen: Endotoxin leads to rapid subcellular relocalization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept. 2, 4(2004)
48. Vos T A, G. J. Hooiveld, H. Koning, S. Childs, D. K. Meijer, H. Moshage, P. L. Jansen, M. Muller: Upregulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology 28, 1637-1644(1998) (Pubitemid 28549135)
49. Zinchuk V, O. Zinchuk, T. Okada: Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: a quantitative colocalization study. Microsc. Res. Tech. 67, 65-70(2005) (Pubitemid 41129255)
50. Elferink M G, P. Olinga, A. L. Draaisma, M. T. Merema, K. N. Faber, M. J. Slooff, D. K. Meijer, G. M. Groothuis: LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am. J. Physiol Gastrointest. Liver Physiol 287, G1008-G1016 (2004) (Pubitemid 39423693)
51. Dikopoulos N, H. Weidenbach, G. Adler, R. M. Schmid: Lipopolysaccharide represses cholesterol 7-alpha hydroxylase and induces binding activity to the bile acid response element II. Eur. J. Clin. Invest 33, 58-64(2003) (Pubitemid 36051292)
52. Feingold K R, D. K. Spady, A. S. Pollock, A. H. Moser, C. Grunfeld: Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J. Lipid Res. 37, 223-228(1996) (Pubitemid 26078941)
53. Zollner G, P. Fickert, A. Fuchsbichler, D. Silbert, M. Wagner, S. Arbeiter, F. J. Gonzalez, H. U. Marschall, K. Zatloukal, H. Denk, M. Trauner: Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J. Hepatol. 39, 480-488(2003) (Pubitemid 37204645)
54. Zollner G, M. Wagner, T. Moustafa, P. Fickert, D. Silbert, J. Gumhold, A. Fuchsbichler, E. Halilbasic, H. Denk, H. U. Marschall, M. Trauner: Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am. J. Physiol Gastrointest. Liver Physiol 290, G923-G932 (2006)
55. Staudinger J L, B. Goodwin, S. A. Jones, D. Hawkins-Brown, K. I. MacKenzie, A. LaTour, Y. Liu, C. D. Klaassen, K. K. Brown, J. Reinhard, T. M. Willson, B. H. Koller, S. A. Kliewer: The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A 98, 3369-3374(2001) (Pubitemid 32220852)
56. Xie W, A. Radominska-Pandya, Y. Shi, C. M. Simon, M. C. Nelson, E. S. Ong, D. J. Waxman, R. M. Evans: An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U. S. A 98, 3375-3380(2001) (Pubitemid 32220853)
57. Cherrington N J, D. P. Hartley, N. Li, D. R. Johnson, C. D. Klaassen: Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther. 300, 97-104(2002) (Pubitemid 34028514)
58. Dietrich C G, D. R. de Waart, R. Ottenhoff, A. H. Bootsma, A. H. van Gennip, R. P. Elferink: Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis 22, 805-811(2001) (Pubitemid 32447929)
59. Zelcer N, T. Saeki, I. Bot, A. Kuil, P. Borst: Transport of bile acids in multidrug-resistanceprotein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem. J. 369, 23-30(2003) (Pubitemid 36174121)
60. Kitada H, M. Miyata, T. Nakamura, A. Tozawa, W. Honma, M. Shimada, K. Nagata, C. J. Sinal, G. L. Guo, F. J. Gonzalez, Y. Yamazoe: Protective role of hydroxysteroid sulfotransferase in lithocholic acidinduced liver toxicity. J. Biol. Chem. 278, 17838-17844(2003) (Pubitemid 36799388)
61. Hirohashi T, H. Suzuki, H. Takikawa, Y. Sugiyama: ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3) J. Biol. Chem. 275, 2905-2910(2000) (Pubitemid 30082066)
62. Akita H, H. Suzuki, T. Hirohashi, H. Takikawa, Y. Sugiyama: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm. Res. 19, 34-41(2002) (Pubitemid 34075104)
63. Akita H, H. Suzuki, K. Ito, S. Kinoshita, N. Sato, H. Takikawa, Y. Sugiyama: Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim. Biophys. Acta 1511, 7-16(2001) (Pubitemid 32206667)
64. Yousef I M, G. Bouchard, B. Tuchweber, G. L. Plaa: Monohydroxy bile acid induced cholestasis: role of biotransformation. Drug Metab Rev. 29, 167-181(1997) (Pubitemid 27293608)
65. Fickert P, A. Fuchsbichler, H. U. Marschall, M. Wagner, G. Zollner, R. Krause, K. Zatloukal, H. Jaeschke, H. Denk, M. Trauner: Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am. J. Pathol. 168, 410-422(2006) (Pubitemid 43271140)
66. Rodriguez-Garay E A: Cholestasis: human disease and experimental animal models. Ann. Hepatol. 2, 150-158(2003)
67. Yamamoto Y, R. Moore, H. A. Hess, G. L. Guo, F. J. Gonzalez, K. S. Korach, R. R. Maronpot, M. Negishi: Estrogen receptor alpha mediates 17alphaethynylestradiol causing hepatotoxicity. J. Biol. Chem. 281, 16625-16631(2006)
68. Fiorucci S, C. Clerici, E. Antonelli, S. Orlandi, B. Goodwin, B. M. Sadeghpour, G. Sabatino, G. Russo, D. Castellani, T. M. Willson, M. Pruzanski, R. Pellicciari, A. Morelli: Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313, 604-612(2005) (Pubitemid 40604160)
69. Kaplan M M & M. E. Gershwin: Primary biliary cirrhosis. N. Engl. J. Med. 353, 1261-1273(2005) (Pubitemid 41345948)
70. Zollner G, M. Wagner, P. Fickert, D. Silbert, J. Gumhold, K. Zatloukal, H. Denk, M. Trauner: Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 27, 920-929(2007) (Pubitemid 47261945)
71. Bertolotti M, L. Carulli, M. Concari, P. Martella, P. Loria, E. Tagliafico, S. Ferrari, M. Del Puppo, B. Amati, E. De Fabiani, M. Crestani, C. Amorotti, A. Manenti, F. Carubbi, A. Pinetti, N. Carulli: Suppression of bile acid synthesis, but not of hepatic cholesterol 7alpha-hydroxylase expression, by obstructive cholestasis in humans. Hepatology 34, 234-242(2001) (Pubitemid 32702334)
72. Naito T, S. Kuroki, K. Chijiiwa, M. Tanaka: Bile acid synthesis and biliary hydrophobicity during obstructive jaundice in rats. J. Surg. Res. 65, 70-76(1996) (Pubitemid 26339197)
73. Raedsch R, B. H. Lauterburg, A. F. Hofmann: Altered bile acid metabolism in primary biliary cirrhosis. Dig. Dis. Sci. 26, 394-401(1981) (Pubitemid 11120725)
74. Batta A K, R. Arora, G. Salen, G. S. Tint, D. Eskreis, S. Katz: Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J. Lipid Res. 30, 1953-1962(1989) (Pubitemid 20030374)
75. Lanzini A, M. G. De Tavonatti, B. Panarotto, S. Scalia, A. Mora, F. Benini, O. Baisini, F. Lanzarotto: Intestinal absorption of the bile acid analogue 75Sehomocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut 52, 1371-1375(2003) (Pubitemid 37026473)
76. Hruz P, C. Zimmermann, H. Gutmann, L. Degen, U. Beuers, L. Terracciano, J. Drewe, C. Beglinger: Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 55, 395-402(2006) (Pubitemid 43273323)
77. Jacquemin E, J. M. De Vree, D. Cresteil, E. M. Sokal, E. Sturm, M. Dumont, G. L. Scheffer, M. Paul, M. Burdelski, P. J. Bosma, O. Bernard, M. Hadchouel, R. P. Elferink: The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120, 1448-1458(2001) (Pubitemid 32322319)
78. Eloranta M L, T. Hakli, M. Hiltunen, S. Helisalmi, K. Punnonen, S. Heinonen: Association of single nucleotide polymorphisms of the bile salt export pump gene with intrahepatic cholestasis of pregnancy. Scand. J. Gastroenterol. 38, 648-652(2003) (Pubitemid 36724045)
79. Mullenbach R, A. Bennett, N. Tetlow, N. Patel, G. Hamilton, F. Cheng, J. Chambers, R. Howard, S. D. Taylor-Robinson, C. Williamson: ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 54, 829-834(2005) (Pubitemid 40732102)
80. Painter J N, M. Savander, A. Ropponen, N. Nupponen, S. Riikonen, O. Ylikorkala, A. E. Lehesjoki, K. Aittomaki: Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur. J. Hum. Genet. 13, 435-439(2005) (Pubitemid 40520934)
81. Sookoian S, G. Castano, A. Burgueno, T. F. Gianotti, C. J. Pirola: Association of the multidrugresistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J. Hepatol. 48, 125-132(2008) (Pubitemid 350191993)
82. Van Mil S W, A. Milona, P. H. Dixon, R. Mullenbach, V. L. Geenes, J. Chambers, V. Shevchuk, G. E. Moore, F. Lammert, A. G. Glantz, L. A. Mattsson, J. Whittaker, M. G. Parker, R. White, C. Williamson: Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133, 507-516(2007) (Pubitemid 47187340)
83. Arrese M, R. I. Macias, O. Briz, M. J. Perez, J. J. Marin: Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert. Rev. Mol. Med. 10, e9 (2008)
84. Chen H L, Y. J. Liu, H. L. Chen, S. H. Wu, Y. H. Ni, M. C. Ho, H. S. Lai, W. M. Hsu, H. C. Tseng, Y. M. Jeng, M. H. Chang: Expression of Hepatocyte Transporters and Nuclear Receptors in Children with Early and Late-Stage Biliary Atresia. Pediatr. Res. (2008)
85. Balistreri W F, J. A. Bezerra, P. Jansen, S. J. Karpen, B. L. Shneider, F. J. Suchy: Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference. Hepatology 42, 222-235(2005) (Pubitemid 40911332)
86. Jansen P L & E. Sturm: Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23, 315-322(2003) (Pubitemid 37259200)
87. Alissa F T, R. Jaffe, B. L. Shneider: Update on progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 46, 241-252(2008)
88. Sinal C J, M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, F. J. Gonzalez: Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744(2000)
89. Alvarez L, P. Jara, E. Sanchez-Sabate, L. Hierro, J. Larrauri, M. C. Diaz, C. Camarena, L. De, V, E. Frauca, E. Lopez-Collazo, P. Lapunzina: Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13, 2451-2460(2004) (Pubitemid 39377849)
90. Chen F, M. Ananthanarayanan, S. Emre, E. Neimark, L. N. Bull, A. S. Knisely, S. S. Strautnieks, R. J. Thompson, M. S. Magid, R. Gordon, N. Balasubramanian, F. J. Suchy, B. L. Shneider: Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126, 756-764(2004) (Pubitemid 38298324)
91. Jansen P L, S. S. Strautnieks, E. Jacquemin, M. Hadchouel, E. M. Sokal, G. J. Hooiveld, J. H. Koning, A. Jager-Krikken, F. Kuipers, F. Stellaard, C. M. Bijleveld, A. Gouw, H. Van Goor, R. J. Thompson, M. Muller: Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117, 1370-1379(1999)
92. Strautnieks S S, J. A. Byrne, L. Pawlikowska, D. Cebecauerova, A. Rayner, L. Dutton, Y. Meier, A. Antoniou, B. Stieger, H. Arnell, F. Ozcay, H. F. Al Hussaini, A. F. Bassas, H. J. Verkade, B. Fischler, A. Nemeth, R. Kotalova, B. L. Shneider, J. Cielecka-Kuszyk, P. McClean, P. F. Whitington, E. Sokal, M. Jirsa, S. H. Wali, I. Jankowska, J. Pawlowska, G. Mieli-Vergani, A. S. Knisely, L. N. Bull, R. J. Thompson: Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134, 1203-1214(2008)
93. Huang L, A. Zhao, J. L. Lew, T. Zhang, Y. Hrywna, J. R. Thompson, N. de Pedro, I. Royo, R. A. Blevins, F. Pelaez, S. D. Wright, J. Cui: Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278, 51085-51090(2003) (Pubitemid 38020343)
94. Whitehead M W, I. Hainsworth, J. G. Kingham: The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 48, 409-413(2001) (Pubitemid 32269572)
95. Hamilton J R & A. Sass-Kortsak: Jaundice associated with severe bacterial infection in young infants. J. Pediatr. 63, 121-132(1963)
96. Albers M J, D. A. Gast-Bakker, N. A. van Dam, G. C. Madern, D. Tibboel: Male sex predisposes the newborn surgical patient to parenteral nutritionassociated cholestasis and to sepsis. Arch. Surg. 137, 789-793(2002) (Pubitemid 34743167)
97. Chand N & A. J. Sanyal: Sepsis-induced cholestasis. Hepatology 45, 230-241(2007) (Pubitemid 46144383)
98. Jansen P L, G. J. Mulder, B. Burchell, K. W. Bock: New developments in glucuronidation research: report of a workshop on "glucuronidation, its role in health and disease". Hepatology 15, 532-544(1992)
99. Roelofsen H, C. T. Bakker, B. Schoemaker, M. Heijn, P. L. Jansen, R. P. Elferink: Redistribution of canalicular organic anion transport activity in isolated and cultured rat hepatocytes. Hepatology 21, 1649-1657(1995)
100. Szabo G, L. Romics, Jr., G. Frendl: Liver in sepsis and systemic inflammatory response syndrome. Clin. Liver Dis. 6, 1045-66, x (2002) (Pubitemid 36026462)
101. Sturm E, R. Havinga, J. F. Baller, H. Wolters, N. van Rooijen, J. A. Kamps, H. J. Verkade, S. J. Karpen, F. Kuipers: Kupffer cell depletion with liposomal clodronate prevents suppression of Ntcp expression in endotoxin-treated rats. J. Hepatol. 42, 102-109(2005) (Pubitemid 40038907)
102. Sturm E, T. L. Zimmerman, A. R. Crawford, S. I. Svetlov, P. Sundaram, J. L. Ferrara, S. J. Karpen, J. M. Crawford: Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line. Hepatology 31, 124-130(2000) (Pubitemid 30033698)
103. Moseley R H, W. Wang, H. Takeda, K. Lown, L. Shick, M. Ananthanarayanan, F. J. Suchy: Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am. J. Physiol 271, G137-G146 (1996) (Pubitemid 26299736)
104. Green R M, D. Beier, J. L. Gollan: Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology 111, 193-198(1996) (Pubitemid 26226899)
105. Whiting J F, R. M. Green, A. B. Rosenbluth, J. L. Gollan: Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxininduced cholestasis. Hepatology 22, 1273-1278(1995)
106. Moseley R H: Sepsis and cholestasis. Clin. Liver Dis. 8, 83-94(2004) (Pubitemid 38373671)
107. Trauner M, M. H. Nathanson, S. A. Rydberg, T. A. Koeppel, C. Gartung, W. C. Sessa, J. L. Boyer: Endotoxin impairs biliary glutathione and. Hepatology 25, 1184-1191(1997)
108. Hartmann G, A. K. Cheung, M. Piquette-Miller: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303, 273-281(2002)
109. Friedman S L: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275, 2247-2250(2000) (Pubitemid 30081976)
110. Friedman S L: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88, 125-172(2008)
111. Vogel S, R. Piantedosi, J. Frank, A. Lalazar, D. C. Rockey, S. L. Friedman, W. S. Blaner: An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J. Lipid Res. 41, 882-893(2000) (Pubitemid 30434319)
112. Wang L, L. R. Tankersley, M. Tang, J. J. Potter, E. Mezey: Regulation of the murine alpha (2) (I) collagen promoter by retinoic acid and retinoid X receptors. Arch. Biochem. Biophys. 401, 262-270(2002) (Pubitemid 34848629)
113. Hellemans K, P. Verbuyst, E. Quartier, F. Schuit, K. Rombouts, R. A. Chandraratna, D. Schuppan, A. Geerts: Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 39, 97-108(2004) (Pubitemid 38461472)
114. Okuno M, T. Sato, T. Kitamoto, S. Imai, N. Kawada, Y. Suzuki, H. Yoshimura, H. Moriwaki, K. Onuki, S. Masushige, Y. Muto, S. L. Friedman, S. Kato, S. Kojima: Increased 9, 13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. J. Hepatol. 30, 1073-1080(1999) (Pubitemid 29278752)
115. Marra F, E. Efsen, R. G. Romanelli, A. Caligiuri, S. Pastacaldi, G. Batignani, A. Bonacchi, R. Caporale, G. Laffi, M. Pinzani, P. Gentilini: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119, 466-478(2000) (Pubitemid 30621997)
116. Miyahara T, L. Schrum, R. Rippe, S. Xiong, H. F. Yee, Jr., K. Motomura, F. A. Anania, T. M. Willson, H. Tsukamoto: Peroxisome proliferatoractivated receptors and hepatic stellate cell activation. J. Biol. Chem. 275, 35715-35722(2000)
117. Zhao C, W. Chen, L. Yang, L. Chen, S. A. Stimpson, A. M. Diehl: PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem. Biophys. Res. Commun. 350, 385-391(2006) (Pubitemid 44498647)
118. Galli A, D. W. Crabb, E. Ceni, R. Salzano, T. Mello, G. Svegliati-Baroni, F. Ridolfi, L. Trozzi, C. Surrenti, A. Casini: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122, 1924-1940(2002) (Pubitemid 34651436)
119. Kawaguchi K, I. Sakaida, M. Tsuchiya, K. Omori, T. Takami, K. Okita: Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem. Biophys. Res. Commun. 315, 187-195(2004) (Pubitemid 38175204)
120. Tomita K, T. Azuma, N. Kitamura, J. Nishida, G. Tamiya, A. Oka, S. Inokuchi, T. Nishimura, M. Suematsu, H. Ishii: Pioglitazone prevents alcoholinduced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126, 873-885(2004) (Pubitemid 38298335)
121. Haughton E L, S. J. Tucker, C. J. Marek, E. Durward, V. Leel, Z. Bascal, T. Monaghan, M. Koruth, E. Collie-Duguid, D. A. Mann, J. E. Trim, M. C. Wright: Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131, 194-209(2006) (Pubitemid 44015746)
122. Marek C J, S. J. Tucker, D. K. Konstantinou, L. J. Elrick, D. Haefner, C. Sigalas, G. I. Murray, B. Goodwin, M. C. Wright: Pregnenolone- 16alphacarbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387, 601-608(2005) (Pubitemid 40685693)
123. Gascon-Barre M, C. Demers, A. Mirshahi, S. Neron, S. Zalzal, A. Nanci: The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 37, 1034-1042(2003) (Pubitemid 36538680)
124. Liu Q H, D. G. Li, X. Huang, C. H. Zong, Q. F. Xu, H. M. Lu: Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J. Gastroenterol. 10, 1315-1320(2004) (Pubitemid 39162438)
125. Shimizu I: Impact of oestrogens on the progression of liver disease. Liver Int. 23, 63-69(2003) (Pubitemid 37265776)
126. Yasuda M, I. Shimizu, M. Shiba, S. Ito: Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 29, 719-727(1999) (Pubitemid 29109585)
127. Raddatz D, M. Henneken, T. Armbrust, G. Ramadori: Subcellular distribution of glucocorticoid receptor in cultured rat and human liver-derived cells and cell lines: influence of dexamethasone. Hepatology 24, 928-933(1996) (Pubitemid 26334297)
128. Fiorucci S, E. Antonelli, G. Rizzo, B. Renga, A. Mencarelli, L. Riccardi, S. Orlandi, R. Pellicciari, A. Morelli: The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-1512(2004) (Pubitemid 39457775)
129. Fiorucci S, G. Rizzo, E. Antonelli, B. Renga, A. Mencarelli, L. Riccardi, A. Morelli, M. Pruzanski, R. Pellicciari: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther. 315, 58-68(2005) (Pubitemid 41380498)
130. Desmet V J: Current problems in diagnosis of biliary disease and cholestasis. Semin. Liver Dis. 6, 233-245(1986) (Pubitemid 17203552)
131. Galon J, D. Franchimont, N. Hiroi, G. Frey, A. Boettner, M. Ehrhart-Bornstein, J. J. O'Shea, G. P. Chrousos, S. R. Bornstein: Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61-71(2002) (Pubitemid 34027951)
132. Joseph S B, A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, P. Tontonoz: Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9, 213-219(2003) (Pubitemid 36227724)
133. Ogawa S, J. Lozach, C. Benner, G. Pascual, R. K. Tangirala, S. Westin, A. Hoffmann, S. Subramaniam, M. David, M. G. Rosenfeld, C. K. Glass: Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122, 707-721(2005) (Pubitemid 41242636)
134. Welch J S, M. Ricote, T. E. Akiyama, F. J. Gonzalez, C. K. Glass: PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A 100, 6712-6717(2003) (Pubitemid 36666645)
135. Pascual G & C. K. Glass: Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab 17, 321-327(2006) (Pubitemid 44397567)
136. Pascual G, A. L. Fong, S. Ogawa, A. Gamliel, A. C. Li, V. Perissi, D. W. Rose, T. M. Willson, M. G. Rosenfeld, C. K. Glass: A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759-763(2005) (Pubitemid 41486547)
137. Zelcer N & P. Tontonoz: Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest 116, 607-614(2006) (Pubitemid 43326865)
138. Caldenhoven E, J. Liden, S. Wissink, S. A. Vande, J. Raaijmakers, L. Koenderman, S. Okret, J. A. Gustafsson, P. T. Van der Saag: Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 9, 401-412(1995)
139. Liden J, F. Delaunay, I. Rafter, J. Gustafsson, S. Okret: A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J. Biol. Chem. 272, 21467-21472(1997) (Pubitemid 27374019)
140. van der B B, J. Liden, S. Okret, F. Delaunay, S. Wissink, P. T. Van der Saag, J. A. Gustafsson: Nuclear Factor-kappa B Repression in Antiinflammation and Immunosuppression by Glucocorticoids. Trends Endocrinol. Metab 8, 152-157(1997) (Pubitemid 27265631)
141. Auphan N, J. A. Didonato, C. Rosette, A. Helmberg, M. Karin: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270, 286-290(1995)
142. Auphan N, J. A. Didonato, A. Helmberg, C. Rosette, M. Karin: Immunoregulatory genes and immunosuppression by glucocorticoids. Arch. Toxicol. Suppl 19, 87-95(1997)
143. Teng S & M. Piquette-Miller: The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther. 312, 841-848(2005) (Pubitemid 40189587)
144. Paunescu E: In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature 228, 1188-1190(1970)
145. Doria G & G. Agarossi: Inhibition of the immune response in vitro by rifampicin and derivatives. Scand. J. Respir. Dis. Suppl 84, 23-26(1973)
146. Ibrahim M S, Z. A. Maged, A. Haron, R. Y. Khalil, A. M. Attallah: Antibiotics and immunity: effects of antibiotics on mitogen responsiveness of lymphocytes and interleukin-2 production. Chemioterapia. 7, 369-372(1988) (Pubitemid 19039750)
147. Dring M M, C. A. Goulding, V. I. Trimble, D. Keegan, A. W. Ryan, K. M. Brophy, C. M. Smyth, P. W. Keeling, D. O'Donoghue, M. O'Sullivan, C. O'Morain, N. Mahmud, A. C. Wikstrom, D. Kelleher, R. McManus: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130, 341-348(2006) (Pubitemid 43202034)
148. Lorenzo-Zuniga V, R. Bartoli, R. Planas, A. F. Hofmann, B. Vinado, L. R. Hagey, J. M. Hernandez, J. Mane, M. A. Alvarez, V. Ausina, M. A. Gassull: Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 37, 551-557(2003) (Pubitemid 36258776)
149. Chang K O & D. W. George: Bile acids promote the expression of hepatitis C virus in repliconharboring cells. J. Virol. 81, 9633-9640(2007) (Pubitemid 350067669)
150. Scholtes C, O. Diaz, V. Icard, A. Kaul, R. Bartenschlager, V. Lotteau, P. Andre: Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J. Hepatol. 48, 192-199(2008)
151. Tang H, K. E. Banks, A. L. Anderson, A. McLachlan: Hepatitis B virus transcription and replication. Drug News Perspect. 14, 325-334(2001) (Pubitemid 32970829)
152. Oropeza C E, L. Li, A. McLachlan: Differential inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by the small heterodimer partner. J. Virol. 82, 3814-3821(2008) (Pubitemid 351521218)
153. van Hengel J, P. D'Hooge, B. Hooghe, X. Wu, L. Libbrecht, R. De Vos, F. Quondamatteo, M. Klempt, C. Brakebusch, F. van Roy: Continuous cell injury promotes hepatic tumorigenesis in cdc42-deficient mouse liver. Gastroenterology 134, 781-792(2008) (Pubitemid 351312733)
154. Knisely A S, S. S. Strautnieks, Y. Meier, B. Stieger, J. A. Byrne, B. C. Portmann, L. N. Bull, L. Pawlikowska, B. Bilezikci, F. Ozcay, A. Laszlo, L. Tiszlavicz, L. Moore, J. Raftos, H. Arnell, B. Fischler, A. Nemeth, N. Papadogiannakis, J. Cielecka-Kuszyk, I. Jankowska, J. Pawlowska, H. Melin-Aldana, K. M. Emerick, P. F. Whitington, G. Mieli-Vergani, R. J. Thompson: Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44, 478-486(2006) (Pubitemid 44214888)
155. Suzuki A, J. Lymp, J. Donlinger, F. Mendes, P. Angulo, K. Lindor: Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 5, 259-264(2007) (Pubitemid 46216931)
156. Bhadri V A, M. O. Stormon, S. Arbuckle, A. H. Lam, K. J. Gaskin, A. Shun: Hepatocellular carcinoma in children with Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 41, 676-678(2005) (Pubitemid 41579683)
157. Jones B A & G. J. Gores: Hepatobiliary malignancy. Clin. Liver Dis. 2, 437-xii (1998)
158. Findor J, X. S. He, J. Sord, R. Terg, M. E. Gershwin: Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun. Rev. 1, 220-225(2002) (Pubitemid 38340256)
159. Katzenellenbogen M, L. Mizrahi, O. Pappo, N. Klopstock, D. Olam, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, E. Domany, E. Galun, D. Goldenberg: Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol. Cancer Res. 5, 1159-1170(2007) (Pubitemid 350137111)
160. Rosen H R: Liver disease associated with alpha1-antitrypsin deficiency. Clin. Liver Dis. 2, 175-185(1998)
161. Lazaridis K N: Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 47, 8-10(2008) (Pubitemid 351171034)
162. Tischendorf J J, P. N. Meier, C. P. Strassburg, J. Klempnauer, H. Hecker, M. P. Manns, M. Kruger: Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand. J. Gastroenterol. 41, 1227-1234(2006) (Pubitemid 44451688)
163. Yu S, S. Rao, J. K. Reddy: Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr. Mol. Med. 3, 561-572(2003) (Pubitemid 37168598)
164. Yeldandi A V, M. S. Rao, J. K. Reddy: Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat. Res. 448, 159-177(2000) (Pubitemid 30139452)
165. Tanaka N, K. Moriya, K. Kiyosawa, K. Koike, F. J. Gonzalez, T. Aoyama: PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest 118, 683-694(2008) (Pubitemid 351206557)
166. Yu J, L. Qiao, L. Zimmermann, M. P. Ebert, H. Zhang, W. Lin, C. Rocken, P. Malfertheiner, G. C. Farrell: Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43, 134-143(2006) (Pubitemid 43733600)
167. Giannitrapani L, M. Soresi, E. La Spada, M. Cervello, N. D'Alessandro, G. Montalto: Sex hormones and risk of liver tumor. Ann. N. Y. Acad. Sci. 1089, 228-236(2006) (Pubitemid 47092098)
168. Zhai Y, G. Zhou, G. Deng, W. Xie, X. Dong, X. Zhang, L. Yu, H. Yang, X. Yuan, H. Zhang, L. Zhi, Z. Yao, Y. Shen, B. Qiang, F. He: Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 130, 2001-2009(2006) (Pubitemid 43816947)
169. Pourgholami M H, J. Akhter, Y. Lu, D. L. Morris: In vitro and in vivo inhibition of liver cancer cells by 1, 25-dihydroxyvitamin D3. Cancer Lett. 151, 97-102(2000) (Pubitemid 30155590)
170. Kim I, K. Morimura, Y. Shah, Q. Yang, J. M. Ward, F. J. Gonzalez: Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940-946(2007) (Pubitemid 47072176)
171. Roy D, S. Sarkar, Q. Felty: Levels of IL-1 beta control stimulatory/inhibitory growth of cancer cells. Front Biosci. 11, 889-898(2006) (Pubitemid 43256429)
172. Guillouzo A, A. Corlu, C. Aninat, D. Glaise, F. Morel, C. Guguen-Guillouzo: The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168, 66-73(2007) (Pubitemid 46659919)
173. Yamamoto Y, R. Moore, T. L. Goldsworthy, M. Negishi, R. R. Maronpot: The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 64, 7197-7200(2004) (Pubitemid 39372050)
174. Pascussi J M, A. Robert, A. Moreau, J. Ramos, P. Bioulac-Sage, F. Navarro, P. Blanc, E. Assenat, P. Maurel, M. J. Vilarem: Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. Hepatology 45, 1146-1153(2007) (Pubitemid 46775776)
175. Masuyama H, Y. Hiramatsu, J. Kodama, T. Kudo: Expression and potential roles of pregnane X receptor in endometrial cancer. J. Clin. Endocrinol. Metab 88, 4446-4454(2003) (Pubitemid 37153756)
176. Zhang Y & P. A. Edwards: FXR signaling in metabolic disease. FEBS Lett. 582, 10-18(2008) (Pubitemid 350297240)
177. Konno Y, M. Negishi, S. Kodama: The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab Pharmacokinet. 23, 8-13(2008)
178. Hansen M K & T. M. Connolly: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drugs 9, 247-255(2008) (Pubitemid 351323377)
179. Jay M A & J. Ren: Peroxisome proliferatoractivated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes Rev. 3, 33-39(2007) (Pubitemid 46592792)
180. Moreau A, M. J. Vilarem, P. Maurel, J. M. Pascussi: Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm. 5, 35-41(2008) (Pubitemid 351300032)
181. Lee J H, J. Zhou, W. Xie: PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. Mol. Pharm. 5, 60-66(2008) (Pubitemid 351300035)
182. George J & C. Liddle: Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5, 49-59(2008) (Pubitemid 351300034)
183. Schroeder F, A. D. Petrescu, H. Huang, B. P. Atshaves, A. L. McIntosh, G. G. Martin, H. A. Hostetler, A. Vespa, D. Landrock, K. K. Landrock, H. R. Payne, A. B. Kier: Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 43, 1-17(2008) (Pubitemid 351206956)
184. Scotti E, F. Gilardi, C. Godio, E. Gers, J. Krneta, N. Mitro, E. De Fabiani, D. Caruso, M. Crestani: Bile acids and their signaling pathways: eclectic regulators of diverse cellular functions. Cell Mol. Life Sci. 64, 2477-2491(2007) (Pubitemid 350035621)
185. Zandbergen F & J. Plutzky: PPARalpha in atherosclerosis and inflammation. Biochim. Biophys. Acta 1771, 972-982(2007)
186. Cariou B & B. Staels: FXR: a promising target for the metabolic syndrome? Trends Pharmacol. Sci. 28, 236-243(2007) (Pubitemid 46661001)
187. Hagey L R, D. L. Crombie, E. Espinosa, M. C. Carey, H. Igimi, A. F. Hofmann: Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J. Lipid Res. 34, 1911-1917(1993) (Pubitemid 23324966)
188. Chen F, M. Ananthanarayanan, S. Emre, E. Neimark, L. N. Bull, A. S. Knisely, S. S. Strautnieks, R. J. Thompson, M. S. Magid, R. Gordon, N. Balasubramanian, F. J. Suchy, B. L. Shneider: Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126, 756-764(2004) (Pubitemid 38298324)
189. Strautnieks S S, L. N. Bull, A. S. Knisely, S. A. Kocoshis, N. Dahl, H. Arnell, E. Sokal, K. Dahan, S. Childs, V. Ling, M. S. Tanner, A. F. Kagalwalla, A. Nemeth, J. Pawlowska, A. Baker, G. Mieli-Vergani, N. B. Freimer, R. M. Gardiner, R. J. Thompson: A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20, 233-238(1998) (Pubitemid 28507666)
190. Paumgartner G & T. Pusl: Medical treatment of cholestatic liver disease. Clin. Liver Dis. 12, 53-80(2008) (Pubitemid 351163144)
191. Parks D J, S. G. Blanchard, R. K. Bledsoe, G. Chandra, T. G. Consler, S. A. Kliewer, J. B. Stimmel, T. M. Willson, A. M. Zavacki, D. D. Moore, J. M. Lehmann: Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365-1368(1999) (Pubitemid 29289664)
192. Makishima M, A. Y. Okamoto, J. J. Repa, H. Tu, R. M. Learned, A. Luk, M. V. Hull, K. D. Lustig, D. J. Mangelsdorf, B. Shan: Identification of a nuclear receptor for bile acids. Science 284, 1362-1365(1999) (Pubitemid 29289663)
193. Lew J L, A. Zhao, J. Yu, L. Huang, N. de Pedro, F. Pelaez, S. D. Wright, J. Cui: The farnesoid X receptor controls gene expression in a ligand-and promoter-selective fashion. J. Biol. Chem. 279, 8856-8861(2004) (Pubitemid 38295944)
194. Schuetz E G, S. Strom, K. Yasuda, V. Lecureur, M. Assem, C. Brimer, J. Lamba, R. B. Kim, V. Ramachandran, B. J. Komoroski, R. Venkataramanan, H. Cai, C. J. Sinal, F. J. Gonzalez, J. D. Schuetz: Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J. Biol. Chem. 276, 39411-39418(2001) (Pubitemid 37371319)
195. Miura T, R. Ouchida, N. Yoshikawa, K. Okamoto, Y. Makino, T. Nakamura, C. Morimoto, I. Makino, H. Tanaka: Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J. Biol. Chem. 276, 47371-47378(2001)
196. Tanaka H & I. Makino: Ursodeoxycholic aciddependent activation of the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 188, 942-948(1992)
197. Pascussi J M, M. Busson-Le Coniat, P. Maurel, M. J. Vilarem: Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol. Endocrinol. 17, 42-55(2003) (Pubitemid 36132658)
198. Marschall H U, M. Wagner, G. Zollner, P. Fickert, U. Diczfalusy, J. Gumhold, D. Silbert, A. Fuchsbichler, L. Benthin, R. Grundstrom, U. Gustafsson, S. Sahlin, C. Einarsson, M. Trauner: Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129, 476-485(2005) (Pubitemid 41096635)
199. Bodin K, L. Bretillon, Y. Aden, L. Bertilsson, U. Broome, C. Einarsson, U. Diczfalusy: Antiepileptic drugs increase plasma levels of 4betahydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J. Biol. Chem. 276, 38685-38689(2001)
200. Gerk P M, W. Li, V. Megaraj, M. Vore: Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J. Pharmacol. Exp. Ther. 320, 893-899(2007) (Pubitemid 46147973)
201. Paumgartner G & U. Beuers: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36, 525-531(2002) (Pubitemid 34977162)
202. Fickert P, M. Wagner, H. U. Marschall, A. Fuchsbichler, G. Zollner, O. Tsybrovskyy, K. Zatloukal, J. Liu, M. P. Waalkes, C. Cover, H. Denk, A. F. Hofmann, H. Jaeschke, M. Trauner: 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130, 465-481(2006) (Pubitemid 43202044)
203. Yoon Y B, L. R. Hagey, A. F. Hofmann, D. Gurantz, E. L. Michelotti, J. H. Steinbach: Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. Gastroenterology 90, 837-852(1986) (Pubitemid 16124759)
204. Schoenfield L J & J. M. Lachin: Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann. Intern. Med. 95, 257-282(1981) (Pubitemid 11052694)
205. Hofmann A F: The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159, 2647-2658(1999)
206. Modica S & A. Moschetta: Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett. 580, 5492-5499(2006) (Pubitemid 44488553)
207. Pellicciari R, S. Fiorucci, E. Camaioni, C. Clerici, G. Costantino, P. R. Maloney, A. Morelli, D. J. Parks, T. M. Willson: 6alpha-ethylchenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569-3572(2002) (Pubitemid 34856095)
208. Liu Y, J. Binz, M. J. Numerick, S. Dennis, G. Luo, B. Desai, K. I. MacKenzie, T. A. Mansfield, S. A. Kliewer, B. Goodwin, S. A. Jones: Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis. J. Clin. Invest 112, 1678-1687(2003) (Pubitemid 38063725)
209. Claudel T, B. Staels, F. Kuipers: The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol. 25, 2020-2030(2005)
210. Moschetta A, A. L. Bookout, D. J. Mangelsdorf: Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10, 1352-1358(2004) (Pubitemid 40022717)
211. Svegliati-Baroni G, F. Ridolfi, R. Hannivoort, S. Saccomanno, M. Homan, S. De Minicis, P. L. Jansen, C. Candelaresi, A. Benedetti, H. Moshage: Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 128, 1042-1055(2005) (Pubitemid 40523554)
212. Zollner G, A. Caligiuri, P. Fickert, M. Wagner, D. Silbert, M. Pinzani, M. Trauner: Expression of bile acid transport and detoxification systems and their regulatory nuclear receptors in human hepatic stellate cells. J Hepatol 46, S135 (2007)
213. Fickert P, G. Zollner, A. Fuchsbichler, C. Stumptner, A. H. Weiglein, F. Lammert, H. U. Marschall, O. Tsybrovskyy, K. Zatloukal, H. Denk, M. Trauner: Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123, 1238-1251(2002)
214. Sorokin A, J. L. Brown, P. D. Thompson: Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 194, 293-299(2007) (Pubitemid 47513107)
215. Huang W, J. Zhang, D. D. Moore: A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J. Clin. Invest 113, 137-143(2004) (Pubitemid 38541640)
216. Kliewer S A & T. M. Willson: Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J. Lipid Res. 43, 359-364(2002) (Pubitemid 34252265)
217. Bachs L, A. Pares, M. Elena, C. Piera, J. Rodes: Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1, 574-576(1989) (Pubitemid 19074002)
218. Bloomer J R & J. L. Boyer: Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82, 310-317(1975)
219. Stiehl A, M. M. Thaler, W. H. Admirand: The effects of phenobarbital on bile salts and bilirubin in patients with intrahepatic and extrahepatic cholestasis. N. Engl. J. Med. 286, 858-861(1972)
220. Cancado E L, R. M. Leitao, F. J. Carrilho, A. A. Laudanna: Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gammaglutamyl transpeptidase. Am. J. Gastroenterol. 93, 1510-1517(1998) (Pubitemid 29075191)
221. Yerushalmi B, R. J. Sokol, M. R. Narkewicz, D. Smith, F. M. Karrer: Use of rifampin for severe pruritus in children with chronic cholestasis. J. Pediatr. Gastroenterol. Nutr. 29, 442-447(1999) (Pubitemid 30346365)
222. Prince M I, A. D. Burt, D. E. Jones: Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50, 436-439(2002) (Pubitemid 34161065)
223. Wagner M, E. Halilbasic, H. U. Marschall, G. Zollner, P. Fickert, C. Langner, K. Zatloukal, H. Denk, M. Trauner: CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42, 420-430(2005) (Pubitemid 41061095)
224. Guo G L, G. Lambert, M. Negishi, J. M. Ward, H. B. Brewer, Jr., S. A. Kliewer, F. J. Gonzalez, C. J. Sinal: Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278, 45062-45071(2003) (Pubitemid 37432638)
225. Maglich J M, J. Watson, P. J. McMillen, B. Goodwin, T. M. Willson, J. T. Moore: The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J. Biol. Chem. 279, 19832-19838(2004) (Pubitemid 38623423)
226. Guo G L, J. S. Moffit, C. J. Nicol, J. M. Ward, L. A. Aleksunes, A. L. Slitt, S. A. Kliewer, J. E. Manautou, F. J. Gonzalez: Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol. Sci. 82, 374-380(2004) (Pubitemid 39600064)
227. Zhang J, W. Huang, S. S. Chua, P. Wei, D. D. Moore: Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298, 422-424(2002) (Pubitemid 35176352)
228. Leuschner M, K. P. Maier, J. Schlichting, S. Strahl, G. Herrmann, H. H. Dahm, H. Ackermann, J. Happ, U. Leuschner: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117, 918-925(1999) (Pubitemid 29468235)
229. Leuschner M, S. Guldutuna, T. You, K. Hubner, S. Bhatti, U. Leuschner: Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J. Hepatol. 25, 49-57(1996) (Pubitemid 26267092)
230. Mitchison H C, J. M. Palmer, M. F. Bassendine, A. J. Watson, C. O. Record, O. F. James: A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J. Hepatol. 15, 336-344(1992)
231. Rautiainen H, P. Karkkainen, A. L. Karvonen, H. Nurmi, P. Pikkarainen, H. Nuutinen, M. Farkkila: Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41, 747-752(2005) (Pubitemid 40462936)
232. Vacca M, M. Krawczyk, M. Petruzzelli, R. C. Sasso, K. J. van Erpecum, G. Palasciano, G. P. Berge-Henegouwen, A. Moschetta, P. Portincasa: Current treatments of primary sclerosing cholangitis. Curr. Med. Chem. 14, 2081-2094(2007) (Pubitemid 47578165)
233. Trauner M, P. Fickert, R. E. Stauber: Inflammation-induced cholestasis. J. Gastroenterol. Hepatol. 14, 946-959(1999) (Pubitemid 29487289)
234. Pascussi J M, S. Gerbal-Chaloin, J. M. Fabre, P. Maurel, M. J. Vilarem: Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol. Pharmacol. 58, 1441-1450(2000)
235. Pascussi J M, L. Drocourt, J. M. Fabre, P. Maurel, M. J. Vilarem: Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol. 58, 361-372(2000) (Pubitemid 30497480)
236. Weitzel C, D. Stark, F. Kullmann, J. Scholmerich, A. Holstege, W. Falk: Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur. J. Gastroenterol. Hepatol. 17, 169-177(2005) (Pubitemid 40349530)
237. Sola S, J. D. Amaral, R. E. Castro, R. M. Ramalho, P. M. Borralho, B. T. Kren, H. Tanaka, C. J. Steer, C. M. Rodrigues: Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 42, 925-934(2005) (Pubitemid 41401131)
238. Arenas F, I. Hervias, M. Uriz, R. Joplin, J. Prieto, J. F. Medina: Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J. Clin. Invest 118, 695-709(2008) (Pubitemid 351206558)
239. Neuschwander-Tetri B A, W. L. Isley, J. C. Oki, S. Ramrakhiani, S. G. Quiason, N. J. Phillips, E. M. Brunt: Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Intern. Med. 129, 38-41(1998) (Pubitemid 28304651)
240. Gitlin N, N. L. Julie, C. L. Spurr, K. N. Lim, H. M. Juarbe: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129, 36-38(1998) (Pubitemid 28304650)
241. Funk C, M. Pantze, L. Jehle, C. Ponelle, G. Scheuermann, M. Lazendic, R. Gasser: Troglitazoneinduced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167, 83-98(2001) (Pubitemid 32830949)
242. Snow K L & R. H. Moseley: Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci. 80, 732-740(2007) (Pubitemid 46107994)
243. Neuschwander-Tetri B A & S. H. Caldwell: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202-1219(2003) (Pubitemid 36538699)
244. Neuschwander-Tetri B A, E. M. Brunt, K. R. Wehmeier, D. Oliver, B. R. Bacon: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-1017(2003) (Pubitemid 37221684)
245. Promrat K, G. Lutchman, G. I. Uwaifo, R. J. Freedman, A. Soza, T. Heller, E. Doo, M. Ghany, A. Premkumar, Y. Park, T. J. Liang, J. A. Yanovski, D. E. Kleiner, J. H. Hoofnagle: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39, 188-196(2004) (Pubitemid 38461481)
246. Lutchman G, K. Promrat, D. E. Kleiner, T. Heller, M. G. Ghany, J. A. Yanovski, T. J. Liang, J. H. Hoofnagle: Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol. 4, 1048-1052(2006) (Pubitemid 44118842)
247. Belfort R, S. A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, R. Berria, J. Z. Ma, S. Dwivedi, R. Havranek, C. Fincke, R. De Fronzo, G. A. Bannayan, S. Schenker, K. Cusi: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307(2006) (Pubitemid 44837778)
248. Lehmann J M, J. M. Lenhard, B. B. Oliver, G. M. Ringold, S. A. Kliewer: Peroxisome proliferatoractivated receptors alpha and gamma are activated by indomethacin and other non-steroidal antiinflammatory drugs. J. Biol. Chem. 272, 3406-3410(1997)
249. Li A C & C. K. Glass: Peroxisome proliferatoractivated receptors alpha and gamma are activated by indomethacin and other non-steroidal antiinflammatory drugs. J. Lipid Res. 45, 2161-2173(2004)
250. Szatmari I, G. Vamosi, P. Brazda, B. L. Balint, S. Benko, L. Szeles, V. Jeney, C. Ozvegy-Laczka, A. Szanto, E. Barta, J. Balla, B. Sarkadi, L. Nagy: Peroxisome proliferator-activated receptor gammaregulated ABCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem. 281, 23812-23823(2006) (Pubitemid 44274157)
251. Chawla A, W. A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak, S. B. Joseph, D. Liao, L. Nagy, P. A. Edwards, L. K. Curtiss, R. M. Evans, P. Tontonoz: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7, 161-171(2001) (Pubitemid 32162909)
252. Kim H I, Y. K. Koh, T. H. Kim, S. K. Kwon, S. S. Im, H. S. Choi, K. S. Kim, Y. H. Ahn: Transcriptional activation of SHP by PPAR-gamma in liver. Biochem. Biophys. Res. Commun. 360, 301-306(2007)
253. Ghose R, J. Mulder, R. J. von Furstenberg, S. Thevananther, F. Kuipers, S. J. Karpen: Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver. J. Hepatol. 46, 115-123(2007) (Pubitemid 44827424)
254. Dubuquoy L, S. Dharancy, S. Nutten, S. Pettersson, J. Auwerx, P. Desreumaux: Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360, 1410-1418(2002) (Pubitemid 35341309)
255. Kanda T, O. Yokosuka, F. Imazeki, H. Saisho: Bezafibrate treatment: a new medical approach for PBC patients? J. Gastroenterol. 38, 573-578(2003) (Pubitemid 36857389)
256. Kurihara T, A. Maeda, M. Shigemoto, K. Yamashita, E. Hashimoto: Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am. J. Gastroenterol. 97, 212-214(2002) (Pubitemid 34059800)
257. Kurihara T, A. Niimi, A. Maeda, M. Shigemoto, K. Yamashita: Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am. J. Gastroenterol. 95, 2990-2992(2000)
258. Nakai S, T. Masaki, K. Kurokohchi, A. Deguchi, M. Nishioka: Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am. J. Gastroenterol. 95, 326-327(2000) (Pubitemid 30041596)
259. Ohmoto K, Y. Mitsui, S. Yamamoto: Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 21, 223-224(2001) (Pubitemid 32586582)
260. Yano K, H. Kato, S. Morita, O. Takahara, H. Ishibashi, R. Furukawa: Is bezafibrate histologically effective for primary biliary cirrhosis? Am. J. Gastroenterol. 97, 1075-1077(2002) (Pubitemid 34408290)
261. Landrier J F, C. Thomas, J. Grober, I. Zaghini, V. Petit, H. Poirier, I. Niot, P. Besnard: The gene encoding the human ileal bile acid-binding protein
262. Kamisako T & Y. Adachi: Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am. J. Gastroenterol. 90, 1187-1188(1995)
263. Kurihara T, M. Akimoto, K. Abe, H. Ishiguro, A. Niimi, A. Maeda, M. Shigemoto, K. Yamashita, I. Yokoyama, Y. Suzuki,.: Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 15, 890-898(1993) (Pubitemid 23339779)
264. Ritzel U, U. Leonhardt, M. Nather, G. Schafer, V. W. Armstrong, G. Ramadori: Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J. Hepatol. 36, 454-458(2002) (Pubitemid 34407331)
265. Stojakovic T, C. Putz-Bankuti, G. Fauler, H. Scharnagl, M. Wagner, V. Stadlbauer, G. Gurakuqi, R. E. Stauber, W. Marz, M. Trauner: Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46, 776-784(2007) (Pubitemid 47436124)
266. Carrella M, D. Feldman, S. Cogoi, A. Csillaghy, P. A. Weinhold: Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat. Hepatology 29, 1825-1832(1999) (Pubitemid 29247057)
267. Hooiveld G J, T. A. Vos, G. L. Scheffer, H. Van Goor, H. Koning, V. Bloks, A. E. Loot, D. K. Meijer, P. L. Jansen, F. Kuipers, M. Muller: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Gastroenterology 117, 678-687(1999) (Pubitemid 29409255)
268. Landrier J F, C. Thomas, J. Grober, H. Duez, F. Percevault, M. Souidi, C. Linard, B. Staels, P. Besnard: Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J. Biol. Chem. 279, 45512-45518(2004) (Pubitemid 39491537)
269. Kok T, V. W. Bloks, H. Wolters, R. Havinga, P. L. Jansen, B. Staels, F. Kuipers: Peroxisome proliferator-activated receptor alpha (PPARalpha) - mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem. J. 369, 539-547(2003) (Pubitemid 36246237)
270. Cindoruk M, M. Kerem, T. Karakan, B. Salman, O. Akin, M. Alper, O. Erdem, S. Unal: Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC. Gastroenterol. 7, 44(2007)
271. Wagner M & M. Trauner: Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann. Hepatol. 4, 77-99(2005)
272. Lehmann J M, D. D. McKee, M. A. Watson, T. M. Willson, J. T. Moore, S. A. Kliewer: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest 102, 1016-1023(1998) (Pubitemid 28419246)
273. Fang H L, S. C. Strom, H. Cai, C. N. Falany, T. A. Kocarek, M. Runge-Morris: Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67, 1257-1267(2005) (Pubitemid 40410426)
274. Willson T M, P. J. Brown, D. D. Sternbach, B. R. Henke: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550(2000) (Pubitemid 30127149)
275. Marrapodi M & J. Y. Chiang: Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41, 514-520(2000) (Pubitemid 30220654)
276. Roglans N, M. Vazquez-Carrera, M. Alegret, F. Novell, D. Zambon, E. Ros, J. C. Laguna, R. M. Sanchez: Fibrates modify the expression of key factors involved in bile-acid synthesis and biliarylipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59, 855-861(2004) (Pubitemid 38333675)
277. Rudling M, B. Angelin, L. Stahle, E. Reihner, S. Sahlin, H. Olivecrona, I. Bjorkhem, C. Einarsson: Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver. J. Clin. Endocrinol. Metab 87, 4307-4313(2002)
278. Patel D D, B. L. Knight, A. K. Soutar, G. F. Gibbons, D. P. Wade: The effect of peroxisomeproliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. Biochem. J. 351 Pt 3, 747-753(2000)
279. Post S M, H. Duez, P. P. Gervois, B. Staels, F. Kuipers, H. M. Princen: Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21, 1840-1845(2001) (Pubitemid 34219790)
280. Pineda T., I. T. Claudel, C. Duval, V. Kosykh, J. C. Fruchart, B. Staels: Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17, 259-272(2003) (Pubitemid 36183149)
281. Makishima M, T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, D. J. Mangelsdorf: Vitamin D receptor as an intestinal bile acid sensor. Science 296, 1313-1316(2002) (Pubitemid 34522785)
282. Chatterjee B, I. Echchgadda, C. S. Song: Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 400, 165-191(2005) (Pubitemid 43052421)
283. Chen X, F. Chen, S. Liu, H. Glaeser, P. A. Dawson, A. F. Hofmann, R. B. Kim, B. L. Shneider, K. S. Pang: Transactivation of rat apical sodiumdependent bile acid transporter and increased bile acid transport by 1alpha, 25-dihydroxyvitamin D3 via the vitamin D receptor. Mol. Pharmacol. 69, 1913-1923(2006) (Pubitemid 43894308)
284. Honjo Y, S. Sasaki, Y. Kobayashi, H. Misawa, H. Nakamura: 1, 25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. J. Endocrinol. 188, 635-643(2006)
285. Baijal P K, D. W. Fitzpatrick, R. P. Bird: Comparative effects of secondary bile acids, deoxycholic and lithocholic acids, on aberrant crypt foci growth in the postinitiation phases of colon carcinogenesis. Nutr. Cancer 31, 81-89(1998) (Pubitemid 28428067)
286. Reddy B S & K. Watanabe: Effect of cholesterol metabolites and promoting effect of lithocholic acid in colon carcinogenesis in germ-free and conventional F344 rats. Cancer Res. 39, 1521-1524(1979) (Pubitemid 9172667)
287. Kishida T, F. Taguchi, L. Feng, A. Tatsuguchi, J. Sato, S. Fujimori, H. Tachikawa, Y. Tamagawa, Y. Yoshida, M. Kobayashi: Analysis of bile acids in colon residual liquid or fecal material in patients with colorectal neoplasia and control subjects. J. Gastroenterol. 32, 306-311(1997) (Pubitemid 27254796)
288. Ou J, H. Tu, B. Shan, A. Luk, R. A. De Bose-Boyd, Y. Bashmakov, J. L. Goldstein, M. S. Brown: Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc. Natl. Acad. Sci. U. S. A 98, 6027-6032(2001) (Pubitemid 32488187)
289. Song C & S. Liao: Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 141, 4180-4184(2000)
290. Song C, R. A. Hiipakka, S. Liao: Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 65, 423-427(2000) (Pubitemid 30628370)
291. Verreault M, K. Senekeo-Effenberger, J. Trottier, J. A. Bonzo, J. Belanger, J. Kaeding, B. Staels, P. Caron, R. H. Tukey, O. Barbier: The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology 44, 368-378(2006) (Pubitemid 44214876)
292. Karpen S. J.: Exercising the nuclear option to treat cholestasis: CAR and PXR ligands. Hepatology 42(2), 266-9(2005) (Pubitemid 41061077)